Article
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis.
Anticancer research - 1 Jan 2020
Gianoncelli Letizia, Spitaleri Gianluca, Passaro Antonio, Radice Davide, Fumagalli Caterina, Del Signore Ester, Stati Valeria, Catania Chiara Matilde, Guerini-Rocco Elena, Barberis Massimo, DE Marinis Filippo
Abstract excerpt
BACKGROUND/AIM: The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS+). PATIENTS AND METHODS: We retrospectively identified NSCLC patients harboring KRAS mutation treated with IO in our Institution. We analyzed the results in comparison to non-KRAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.